---
title: "Pfizer filed a lawsuit aimed at blocking Novo Nordisk's acquisition of the obesity drug company Metsera"
description: "Pfizer has filed a lawsuit against Metsera Inc. and Novo Nordisk AS, aiming to block Novo Nordisk's acquisition of Metsera. Pfizer is requesting the Delaware court in the United States to halt the tra"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263813901.md"
published_at: "2025-10-31T22:32:13.000Z"
---

# Pfizer filed a lawsuit aimed at blocking Novo Nordisk's acquisition of the obesity drug company Metsera

> Pfizer has filed a lawsuit against Metsera Inc. and Novo Nordisk AS, aiming to block Novo Nordisk's acquisition of Metsera. Pfizer is requesting the Delaware court in the United States to halt the transaction in order to obtain a hearing. Pfizer believes that Novo Nordisk's offer does not meet the criteria for a "superior company proposal." Meanwhile, U.S. antitrust enforcement agencies have approved Pfizer to continue pursuing its acquisition offer for Metsera

Pfizer has sued Metsera Inc. and Novo Nordisk AS, seeking to block Novo Nordisk's competitive acquisition of this emerging obesity drug company. Pfizer is requesting the Delaware Chancery Court to prevent Metsera from completing the transaction with Novo Nordisk, allowing Pfizer time to obtain a hearing. Pfizer stated that under the merger agreement, Novo Nordisk's offer does not meet the criteria for a "Superior Company Proposal." Pfizer announced that U.S. antitrust enforcement agencies have approved its continued pursuit of the acquisition offer for Metsera, stating that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act has ended, "satisfying the regulatory review requirements for the proposed acquisition."

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)
- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J 在诺和诺德公司 $NVO 拥有价值 32 万美元的股票持仓 | Puzo Michael J 在第三季度大幅减持了 Novo Nordisk A/S (NYSE:NVO) 的股份，减少幅度达到 86.9%，目前持有 5,775 股，价值 320,000 美元。其他机构投资者也调整了他们的持仓，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 高盛：诺和诺德定价压力被市场过度定价，口服 Wegovy 将是扭转信心的关键 | 高盛称，当前股价已完全消化 2026 财年最悲观预期。市场低估了 Medicare 放开的销量潜力和口服版 Wegovy 的收入前景。口服 Wegovy 上市表现强劲，已开出 5 万张处方，其中 9 成为自费需求，显示刚性市场潜力，将成为扭 | [Link](https://longbridge.com/en/news/275095024.md) |
| 诺和诺德公司提议任命两名新的董事会成员 | 丹麦制药公司诺和诺德公司提议在 3 月 26 日于哥本哈根举行的年度股东大会上新增三名董事会成员。提议的成员包括海伦娜·萨克森、扬·范·德·温克尔和拉莫娜·塞奎拉。萨克森此前已宣布辞去 Sobi 的职务以加入诺和诺德。还提议重新选举董事长拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| GLP-1 抗肥胖药物在美国市场的四张图表 | 瑞士银行的分析师们在马修·韦斯顿的带领下，分析了美国 GLP-1 抗肥胖药物市场的趋势，重点关注 Wegovy 的新品牌处方（NBRx）。数据显示，Wegovy 的新品牌处方趋势强劲，新推出的 Wegovy 药丸对其影响甚微。即将发生的关键 | [Link](https://longbridge.com/en/news/276280378.md) |
| 诺和诺德公司 - 股份回购计划 | 诺和诺德公司已启动一项最高达 150 亿丹麦克朗的股票回购计划，计划于 2026 年 2 月 4 日开始。截至 2026 年 2 月 13 日，公司已回购 1,750,000 股 B 类股票，平均价格为 305.03 丹麦克朗，总计为 53 | [Link](https://longbridge.com/en/news/276056741.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
